Durie B G, Dalton W S
Department of Internal Medicine, College of Medicine, Arizona Health Sciences Center, Tucson 85724.
Br J Haematol. 1988 Feb;68(2):203-6. doi: 10.1111/j.1365-2141.1988.tb06190.x.
In vitro testing with a new doxorubicin resistant myeloma cell line revealed the reversal of drug resistance with as little as 100 ng/ml of verapamil (a calcium channel blocker), a dose easily achievable in humans. A first patient with IgG kappa myeloma is presented in whom resistance to VAD (vincristine/doxorubicin infusion plus dexamethasone) chemotherapy was reversed with the administration of verapamil. A subsequent clinical study has been initiated. The potential for further evaluation of calcium channel blockers in multiple myeloma is discussed.
对一种新的多柔比星耐药骨髓瘤细胞系进行的体外试验显示，仅用100纳克/毫升维拉帕米（一种钙通道阻滞剂）就能逆转耐药性，这一剂量在人体中很容易达到。本文介绍了首例IgG κ型骨髓瘤患者，其对VAD（长春新碱/多柔比星输注加地塞米松）化疗的耐药性通过给予维拉帕米得以逆转。随后启动了一项临床研究。文中讨论了在多发性骨髓瘤中进一步评估钙通道阻滞剂的潜力。
